Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts

HIV Infection

Free Subscription 14.04.2025 5 AIDS 2 AIDS Res Hum Retroviruses 1 BMC Immunol 3 Clin Infect Dis 2 HIV Med 1 Int J Dermatol 11 J Acquir Immune Defic Syndr 1 J Infect Dis 4 J Virol 3 Lancet 1 Nat Med 2 Pediatr Infect Dis J 5 PLoS One 2 PLoS Pathog

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AIDS

1. BOUWMEESTER TA, van der Wulp IAJ, Kusi Mensah YA, Wit FWNM, et al
   Impaired autonomic cardiovascular control in people with HIV on long-term successful treatment.
   AIDS. 2025 Apr 10. doi: 10.1097/QAD.0000000000004208.
   PubMed         Abstract available
   
   
2. DUARTE HA, Birnbaum JK, Carlucci JG, Ghazal Y, et al
   Modeling the potential impact of viral load monitoring on vertical transmission of HIV in Kenya.
   AIDS. 2025 Apr 10. doi: 10.1097/QAD.0000000000004207.
   PubMed         Abstract available
   
   
3. LI Y, Soto-Ramirez ZN, Roscher J, Medvec T, et al
   Senescence-related cytokine levels are associated with HIV-1 serostatus and persistence.
   AIDS. 2025 Apr 9. doi: 10.1097/QAD.0000000000004204.
   PubMed         Abstract available
   
   
4. VAN DER MANNEN JS, Furamera S, Pienaar J, Komane P, et al
   Predictors of unsuppressed viral load among men who have sex with men living with HIV in South Africa.
   AIDS. 2025 Apr 9. doi: 10.1097/QAD.0000000000004205.
   PubMed         Abstract available
   
   
5. WANG L, Li SM, Li X, Wu HS, et al
   The transmembrane nucleoporin Nup210 weakens HIV-1 infection via modulating late events of viral nuclear import.
   AIDS. 2025 Apr 9. doi: 10.1097/QAD.0000000000004206.
   PubMed         Abstract available
   
   

   
   AIDS Res Hum Retroviruses

6. SHEN K, Feng Y, Wang C, Han J, et al
   Sequence Notes: Characterization of the Near-Full-Length Genome of Two Novel Unique Recombinant Genome (CRF01_AE/CRF79_0107, CRF01_AE/CRF07_BC) in Hebei, China.
   AIDS Res Hum Retroviruses. 2025 Apr 10. doi: 10.1089/aid.2024.0127.
   PubMed         Abstract available
   
   
7. WANG L, Yan M, Wumaierjiang R, Zhang Q, et al
   The Association Between the History of Switching Antiretroviral Therapy Regimens and Lipid Profile in People Living with HIV: A Retrospective Study.
   AIDS Res Hum Retroviruses. 2025 Apr 7. doi: 10.1089/aid.2024.0079.
   PubMed         Abstract available
   
   

   
   BMC Immunol

8. CHUKWUANUKWU RC, Agu CE, Ehiaghe A, Ezeagwuna D, et al
   Markers of neutrophil activation and some immune and haematological indices in malaria infection during pregnancy.
   BMC Immunol. 2025;26:28.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

9. HILL A, Siedner MJ, Fairhead C, Venter F, et al
   The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic.
   Clin Infect Dis. 2025 Apr 9:ciaf115. doi: 10.1093.
   PubMed         Abstract available
   
   
10. BAETEN JM
    Lenacapavir for Human Immunodeficiency Virus (HIV) Prevention: A Commitment to Equitable Access and Partnership by Gilead Sciences.
    Clin Infect Dis. 2025 Apr 9:ciaf116. doi: 10.1093.
    PubMed         Abstract available
    
    
11. SCOTT K, O'Rourke J, Jackson C, Ene L, et al
    Viral suppression, viral failure and safety outcomes in children and adolescents living with HIV on dolutegravir in Europe and Thailand.
    Clin Infect Dis. 2025 Apr 11:ciaf191. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    HIV Med

12. ZUBAIR A, Ahmad H, Arif MM, Ali M, et al
    mRNA vaccines against HIV: Hopes and challenges.
    HIV Med. 2025 Apr 7. doi: 10.1111/hiv.70024.
    PubMed         Abstract available
    
    
13. BARDA B, Barilaro G, Bellini P, Turicchi G, et al
    Efficacy of long-acting cabotegravir plus rilpivirine in viraemic people living with HIV: A systematic review and meta-analysis.
    HIV Med. 2025 Apr 9. doi: 10.1111/hiv.70025.
    PubMed         Abstract available
    
    

    
    Int J Dermatol

14. DARAMUS IA, Tanasov A, Oana AA, Motoi MM, et al
    Cutaneous Cryptococcosis in a Syphilis Patient Newly Diagnosed With Advanced HIV.
    Int J Dermatol. 2025 Apr 9. doi: 10.1111/ijd.17777.
    PubMed        
    
    

    
    J Acquir Immune Defic Syndr

15. WANG H, Delnoij M, Zimmermann HML, Jonas KJ, et al
    The Disparities of PrEP Adherence Among Men Who Have Sex With Men Between the Global South and the Global North: An Updated Determinantal Global Meta-Analysis.
    J Acquir Immune Defic Syndr. 2025;99:1-8.
    PubMed         Abstract available
    
    
16. JAROLIMOVA J, Yan J, Govere S, Shezi S, et al
    Sexually transmitted infection testing integrated with HIV prevention and contraceptive services in hair salons in urban South Africa.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003677.
    PubMed         Abstract available
    
    
17. IZQUIERDO R, Vallejo A, Suarez-Garcia I, Martin-Hondarza A, et al
    Markers of inflammation and immune dysfunction and non-AIDS cancer risk in adults with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003667.
    PubMed         Abstract available
    
    
18. BUNTING SR, Feinstein BA, Wilson A, Rivera J, et al
    Preferences for PrEP Implementation and Engagement in the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum among Patients Receiving Psychiatric Care in an Ending the HIV Epidemic Priority County.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003675.
    PubMed         Abstract available
    
    
19. MOROZOVA O, Conroy K, Riabokon S, Germanovich M, et al
    HIV Viral Rebound on Dolutegravir, Lopinavir and Efavirenz: National Program Data Analysis from Ukraine.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003676.
    PubMed         Abstract available
    
    
20. WALL KM, Sullivan P, Shrestha RK, Dana R, et al
    Cost and cost-effectiveness of online recruitment to increase HIV self-testing among Black and Hispanic/Latino men who have sex with men in the United States, 2020-2021.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003666.
    PubMed         Abstract available
    
    
21. CHEN Y, Montano MA, Naik P, Thuo N, et al
    Incremental cost of pre- and post-exposure prophylaxis service provision via an online pharmacy in Kenya.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003680.
    PubMed         Abstract available
    
    
22. ZHU W, Huang YA, Kourtis AP, Neblett-Fanfair R, et al
    Trends in HIV preexposure prophylaxis use before and after launch of the Ending the HIV Epidemic in the U.S. initiative, 2016-2023.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003674.
    PubMed         Abstract available
    
    
23. MILICIC A, Wilson S, Javandel S, Allen IE, et al
    Plasma Inflammatory Biomarkers Link to Worse Cognition Among Africans with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003679.
    PubMed         Abstract available
    
    
24. ATUJUNA M, Nyamaizi AM, Duby Z, Minnis A, et al
    Men's Voices on Long-Acting Pre-Exposure Prophylaxis Delivery Modalities: Acceptability and Preferences Among Cisgender Men and Men Who Have Sex With Men in South Africa.
    J Acquir Immune Defic Syndr. 2025;99:55-63.
    PubMed         Abstract available
    
    
25. SETIA WIRAWAN GB, Navin KS, Lila Wulandari LP, Boettiger D, et al
    Retention and viral suppression with differentiated time or space for adolescent and young adult HIV care: a systematic review and meta-analysis.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003681.
    PubMed         Abstract available
    
    

    
    J Infect Dis

26. LOURENS R, Singh G, Arendse T, Thwaites G, et al
    Tuberculous meningitis across the lifespan.
    J Infect Dis. 2025 Apr 8:jiaf181. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

27. HUANG Y, Liang G, Wang T, Ma Y, et al
    Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antivirals.
    J Virol. 2025 Apr 10:e0228924. doi: 10.1128/jvi.02289.
    PubMed         Abstract available
    
    
28. WU C, Johnson NM, Yu S, Lo AS, et al
    Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy.
    J Virol. 2025 Apr 10:e0193324. doi: 10.1128/jvi.01933.
    PubMed         Abstract available
    
    
29. CHAUDHURI E, Jang S, Chakraborty R, Radhakrishnan R, et al
    CPSF6 promotes HIV-1 preintegration complex function.
    J Virol. 2025 Apr 9:e0049025. doi: 10.1128/jvi.00490.
    PubMed         Abstract available
    
    
30. VIOX EG, Richard J, Grandea AG 3rd, Nguyen K, et al
    Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques.
    J Virol. 2025 Apr 7:e0006225. doi: 10.1128/jvi.00062.
    PubMed         Abstract available
    
    

    
    Lancet

31. OKANO JT, Blower S
    Long-acting HIV preventive treatments for remote rural communities.
    Lancet. 2025;405:1143.
    PubMed        
    
    
32. CLUVER L, Makangila G, Hillis S, Ntwali-N'Konzi JP, et al
    Protecting Africa's children from extreme risk: a runway of sustainability for PEPFAR programmes.
    Lancet. 2025 Apr 8:S0140-6736(25)00401-5. doi: 10.1016/S0140-6736(25)00401.
    PubMed         Abstract available
    
    
33. SIDIBE M, Makgoba TC, Paul B, Brilliant B, et al
    Accelerating domestic investments to end AIDS in Africa.
    Lancet. 2025 Apr 8:S0140-6736(25)00685-3. doi: 10.1016/S0140-6736(25)00685.
    PubMed        
    
    

    
    Nat Med

34. ZHANG Y, Li J, Xie Y, Wu D, et al
    Author Correction: Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial.
    Nat Med. 2025 Apr 9. doi: 10.1038/s41591-025-03690.
    PubMed        
    
    

    
    Pediatr Infect Dis J

35. FOUGERE Y, Brophy J, Hawkes MT, Lee T, et al
    Clinical and Immunologic Impact of CMV Coinfection Among Children Living With HIV in Canada.
    Pediatr Infect Dis J. 2025 Apr 3. doi: 10.1097/INF.0000000000004811.
    PubMed         Abstract available
    
    
36. JACOBS TG, Ooms GI, Mantel-Teeuwisse AK, Suleman F, et al
    Commentary: Pediatric HIV Treatment: Nurturing Access Through Health Facility Availability and Stock-out Monitoring.
    Pediatr Infect Dis J. 2025 Apr 3. doi: 10.1097/INF.0000000000004814.
    PubMed        
    
    

    
    PLoS One

37. BAKIC M, Stevanovic J, Milic M, Galic I, et al
    Factors associated with the prevalence of viral hepatitis B and C among prisoners: Results of two consecutive national surveys in Montenegro.
    PLoS One. 2025;20:e0321464.
    PubMed         Abstract available
    
    
38. MOSES N, Bukke SPN, Goruntla N, Mwandah DC, et al
    Prevalence and factors associated with adverse drug reactions among patients on highly active antiretroviral therapy at a tertiary hospital in south western Uganda: A cross-sectional study.
    PLoS One. 2025;20:e0321015.
    PubMed         Abstract available
    
    
39. EMMANUEL GO, Umoh P, Amechi P, Sanni OF, et al
    Prevalence of HIV and willingness to uptake preventive services among female sex workers in Kano State, Nigeria.
    PLoS One. 2025;20:e0319942.
    PubMed         Abstract available
    
    
40. CHERNOFSKY A, Lok JJ
    Causal mediation analysis for time-to-event outcomes on the Restricted Mean Survival Time scale: A pseudo-value approach.
    PLoS One. 2025;20:e0319074.
    PubMed         Abstract available
    
    
41. KENYA S, Young B, Escarfuller S, Jones-Weiss D, et al
    Improving HIV outcomes in Miami's Black populations with clinic-based community health workers protocol: The integrated navigation and support for treatment adherence, counseling, and research (INSTACARE) randomized controlled trial.
    PLoS One. 2025;20:e0316300.
    PubMed         Abstract available
    
    

    
    PLoS Pathog

42. FAIZO AAA, Bellward C, Hernandez-Lopez HR, Stevenson A, et al
    The splicing factor kinase, SR protein kinase 1 (SRPK1) is essential for late events in the human papillomavirus life cycle.
    PLoS Pathog. 2025;21:e1012697.
    PubMed         Abstract available
    
    
43. ASHOKKUMAR M, Hafer TL, Felton A, Archin NM, et al
    A targeted CRISPR screen identifies ETS1 as a regulator of HIV-1 latency.
    PLoS Pathog. 2025;21:e1012467.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.